Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: A comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study

Circulation

Volumn 106, Issue 13, 2002, Pages 1627-1633

  Srinivas, V S ^a   Brooks, Maria Mori ^b   Detre, Katherine M ^b   King III, Spencer B ^c   Jacobs, Alice K ^d   Johnston, Janet ^b   Williams, David O ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Fuqua Heart Center   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

Author keywords

Angioplasty; Coronary disease; Registries; Stents; Trials

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RISK ASSESSMENT; SAFETY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CANADA; CLINICAL TRIALS; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; MYOCARDIAL REVASCULARIZATION; NATIONAL INSTITUTES OF HEALTH (U.S.); PROPORTIONAL HAZARDS MODELS; REGISTRIES; REOPERATION; STENTS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0037167720     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000031570.27023.79     Document Type: Article

References (18)

1. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-225.
2. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1999;99:633-640.
3. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute registries. Circulation. 2000;102:2945-2951.
4. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med. 1994;331:489-495.
5. Fischman DL, Leon MD, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
6. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integfin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994;343:881-886.
7. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
8. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 1998;352:87-92.
9. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial. A randomized controlled trial. JAMA. 2001;285:2468-2473.
10. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624-629.
11. Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation. 1997;96:2162-2170.
12. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2002;37:2215-2238.
13. Pocock SJ, Henderson RA, Rickards A, et al. A meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet. 1995;346:1184-1189.
14. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
15. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study. Coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. J Am Coll Cardiol. 2001;37:51-58.
16. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
17. The Eraser Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999;100:799-806.
18. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001;89:305-316.